Details of the Drug Combinations

General Information of This Drug (ID: DM4N7BT)

Drug Name

Paritaprevir DM4N7BT

Synonyms

(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C	1E51	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agent

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Paritaprevir + Ritonavir	DCX4D34	Ritonavir	HCV Infection	[2]
Paritaprevir + ABT-333	DCEUHY4	ABT-333	Chronic Hepatitis C	[3]
Paritaprevir + Ombitasvir	DC3CYMQ	Ombitasvir	Hepatitis C Virus	[4]
------------------------------------------------------------------------------------

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Paritaprevir + Ombitasvir	DC2FWU4	Ombitasvir	Hepatitis C virus infection	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT00850044) Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
3	ClinicalTrials.gov (NCT01464827) ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
4	ClinicalTrials.gov (NCT01458535) A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Nave Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
5	FDA Approved Drug Products from FDA Official Website. 2015. Application Number: (ANDA) 207931.